Skip to main content
. 2017 Nov 27;8(65):109596–109608. doi: 10.18632/oncotarget.22741

Figure 2. In vivo Cisplatin resistance of Cisplatin-treated SCLC cells.

Figure 2

The plot shows the tumor volume from the SCID mice implanted with H69 and CRSC cells, Cisplatin injections started 3 weeks after the implantation. (*, P < 0.05, **, p < 0.01, H69 vs. CRSC).